SCHEMBL8480688

SCHEMBL8480688

O=C(CBr)NCc1cccc(O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
ALOX15 P16050 1/20 0.53
NFKB1 P19838 1/20 0.53
MAPK1 P28482 1/20 0.53
NLRP3 Q96P20 1/20 0.52
KDM4E B2RXH2 2/20 0.51
KMT2A Q03164 1/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
BLM P54132 1/20 0.51
PMP22 Q01453 1/20 0.51
ROCK2 O75116 1/20 0.50
ROCK1 Q13464 1/20 0.50
SRC P12931 1/20 0.49
GABRP O00591 1/20 0.47
GABRD O14764 1/20 0.47
GABRA1 P14867 1/20 0.47
GABRB1 P18505 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL934634 0.83 CYP3A4 (0.53) PKMCYP1A2CYP3A4ALOX15NFKB1
SCHEMBL24499495 0.83 NPC1 (0.61) LMNAMAPTAOC3
SCHEMBL29625240 0.83 NPC1 (0.61) KMT2A
SCHEMBL24499496 0.83 NPC1 (0.61) KMT2A
SCHEMBL28822092 0.81 SRC (0.61) MAPK1KDM4EKMT2ASRC
SCHEMBL14677951 0.81 NOS2 (0.50) PKMKDM4EKMT2AAOC3HDAC6
SCHEMBL29625256 0.81 MMP13 (0.56) KDM4ELMNA
SCHEMBL28738240 0.81 MMP13 (0.56) KDM4ELMNA
SCHEMBL2806074 0.80 CYP1A2 (0.59) PKMCYP1A2CYP3A4ALOX15NFKB1
SCHEMBL2286641 0.80 GAA (0.66) KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD TOPAZ THERAPEUTICS INC (US) 2026-01-22 US disclosed
US-5935950-A AN ANTIBIOTIC COMPRISING A PYRIDINIUM RING WHICH CAN HYDROLYZABLE IN VIVO HOFFMANN-LA ROCHE INC. (US) 1999-08-10 US disclosed
EP-0838465-A1 Pyridinium-substituted (lactamylvinyl)cephalosporin derivatives, their preparation and their use as antibiotics F. HOFFMANN-LA ROCHE AG (CH) 1998-04-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260021192-A1 PROTEINS HAVING A COVALENT WARHEAD RIOX2, ORC3, DCLRE1A PKM 4721/4885CYP1A2 4723/4885CYP3A4 4706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.